Mauna Kea Technologies Introduces Its Needle-Based Cellvizio
Endomicroscopy Solution for Applications in Lung Cancer and Other
Pulmonary Diseases During the European Respiratory Society (ERS)
International Congress 2018

The availability of the needle-based Cellvizio platform, now
bearing CE mark, could be a game changer for the management of
patients with certain pulmonary diseases including lung cancer.

Ground-breaking work from the interventional pulmonology team at
the Amsterdam Academic Medical Center will be highlighted among five
other presentation sessions during ERS, the largest meeting of
respiratory professionals in the world.

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext:
MKEA) inventor of Cellvizio®, the multidisciplinary confocal laser
endomicroscopy (CLE) platform, today announced the introduction of its
needle-based Cellvizio solution for use in lung cancer and respiratory
diseases applications during the European Respiratory Society (ERS)
International Congress 2018, being held September 15-19, in Paris,
France.

During the congress there will be an oral presentation from Dr. Lizzy
Wijmans, Amsterdam, Netherlands on the topic of needle-based Confocal
Laser Endomicroscopy (nCLE) for Diagnosing Malignant Pleural
Mesothelioma, showing positive results for Cellvizio. There are also
five additional presentations using needle-based Confocal Laser
Endomicroscopy across different indications showing the growing momentum
of the Cellvizio platform in pulmonology.

“Our presence and robust presentation schedule at this year’s ERS
congress reflects the introduction of our ground-breaking needle-based
endomicroscopy solution in the lung disease space. These presentations
add to the growing body of evidence for Cellvizio as a valuable tool for
the detection, diagnosis and treatment management of a range of
pulmonary diseases,” said Sacha Loiseau, Ph.D., Founder and Chief
Executive Officer of Mauna Kea Technologies. “In particular, the unique
ability of Cellvizio to get to the core of pulmonary lesions through a
needle is a unique offer which could dramatically improve the management
of patients with suspicion of lung cancer. This opens up important
possibilities for Cellvizio in the management of the second most
prevalent cancer worldwide.”

Mauna Kea Technologies is a global medical device company focused on
eliminating uncertainties related to the diagnosis and treatment of
cancer and other diseases thanks to real time in vivo microscopic
visualization. The Company’s flagship product, Cellvizio®, has received
clearance/approval in a wide range of applications in more than 40
countries, including the United States, Europe, Japan, China, Canada,
Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release contains forward-looking statements concerning Mauna
Kea Technologies and its activities. Such forward looking statements are
based on assumptions that Mauna Kea Technologies considers to be
reasonable. However, there can be no assurance that the anticipated
events contained in such forward-looking statements will occur. Forward-
looking statements are subject to numerous risks and uncertainties
including the risks set forth in the registration document of Mauna Kea
Technologies registered by the French Financial Markets Authority
(Autorité des marchés financiers (AMF)) on April 27, 2018 under number
R.18-0429 and available on the Company's website (www.maunakeatech.com),
and to the development of economic situation, financial markets, and the
markets in which Mauna Kea Technologies operates. The forward-looking
statements contained in this release are also subject to risks unknown
to Mauna Kea Technologies or that Mauna Kea Technologies does not
consider material at this time. The realization of all or part of these
risks could lead to actual results, financial conditions, performances
or achievements by Mauna Kea Technologies that differ significantly from
the results, financial conditions, performances or achievements
expressed in such forward-looking statements. This press release and the
information it contains do not constitute an offer to sell or to
subscribe for, or a solicitation of an order to purchase or subscribe
for, Mauna Kea Technologies shares in any country.